TrialCardiovascular diabetology2020

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

Masato Furuhashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.